Tourette Syndrome Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Tourette Syndrome Treatment Market is segmented by Product (Antipsychotics and Non-Antipsychotics) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Market Snapshot
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 10.4 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Tourette syndrome treatment market is expected to register a CAGR of 10.4% over the forecast period. 

The disruption in the supply chain during COVID-19 and the delay in the delivery of essential products required for the treatment had an adverse impact on the Tourette syndrome treatment market. Some major issues faced by the market players during the pandemic include trucking bottlenecks and port checkpoints slowing down their deliveries, including critical supplies; export bans imposed in many countries; only a few manufacturing units were functional; lack of healthcare workers to transport and manufacture products; lack of proper coordination and alignment among federal, local, and state agencies as well as among healthcare organizations, which led to a fragmented approach towards treatment of patients. Therefore, the market witnessed a slow growth in the initial pandemic phase. 

However, the outbreak of COVID-19 increased the rate of Tourette syndrome within the patient population, also termed tic-like behavior, among all age groups. According to the study titled, " Rapid onset of functional tic-like behaviors in young adults during the COVID-19 pandemic" published in November 2021, doctors have reported an increase in functional tic-like behaviors in children and youth during the COVID-19 pandemic. The report also said that rapid-onset of tic-like behavior is a distinct subtype of a functional neurological disorder that emerged during the COVID-19 pandemic in young people and appears to be strongly socially influenced. Furthermore, as per the study titled, "Increase in Tics in Girls During the COVID-19 Pandemic: Case Series and Literature Review" published in September 2021, an increase in the exacerbation of tic symptoms in patients with a proven tic disorder has been witnessed during the outbreak. It also reported that increased stress and anxiety, change or lack of routine, and reduced distraction or physical activity due to lockdown may be the possible underlying reasons for Tourette syndrome in individuals with a possible underlying genetic vulnerability. Therefore, such instances positively impacted the market growth rate in the latter phase of the pandemic. 

The major factors driving the growth of the market are the increasing cases of Tourette syndrome across the globe and the rising focus on Tourette syndrome research. For instance, according to the journal published by the Cleveland Clinic in February 2021, more than 200,000 people in the United States have a severe form of Tourette syndrome. In addition, increasing research work and studies on Tourette syndrome to investigate underlying causes and treatment efficacy across the globe are also anticipated to propel market growth. 

However, a lack of awareness about Tourette syndrome in developing regions is likely to impede the market's growth over the forecast period.

Scope of the Report

As per the scope of the report, Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements, and vocalizations called tics. It usually affects children aged between six years and 17 years. Tourette syndrome is associated with other additional neurobehavioral problems such as inattention, impulsivity (attention deficit hyperactivity disorder-ADHD), problems with reading and writing, and obsessive-compulsive symptoms. The Tourette syndrome treatment market is segmented by Product (Antipsychotics and Non-Antipsychotics) and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Product
Non Antipsychotics
North America
United States
United Kingdom
Rest of Europe
Asia Pacific
South Korea
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Antipsychotic Segment is Expected to Witness Growth Over the Forecast Period

Antipsychotic drugs are expected to hold the largest market share due to their ability to treat tics to a greater extent as compared to non-antipsychotic drugs. Antipsychotic drugs were developed for the treatment of schizophrenia, hence the term antipsychotic. These medications work by blocking another chemical in the brain called dopamine, specifically by blocking dopamine receptors, mainly the D2 receptor. Thus, such a robust therapeutic effect of antipsychotics is one of the significant factors driving the growth of the segment over the forecast period.

The increasing use of antipsychotic drugs and their efficacy in treating Tourette syndrome is one of the major factors driving the segment's growth over the forecast period. For instance, as per the study titled, "Efficacy of Behavioural Intervention, Antipsychotics, and Alpha Agonists in the Treatment of Tics Disorder in Tourette’s Syndrome" published in February 2022, antipsychotic drugs have been commonly used as a treatment for Tourette syndrome since Food and Drug Administration approval. Haloperidol and pimozide have been used for a long time and have shown significant efficacy. Haloperidol can cause a 91.0% reduction in the severity of tics when given at the maximum dose.

Therefore, such instances indicate that the antipsychotic drugs segment is anticipated to witness a considerable growth rate over the forecast period.


North America is Expected to Dominate the Tourette Syndrome Treatment Market Over the Forecast Period

North America is expected to dominate the overall Tourette syndrome treatment market over the forecast period. The growth is due to factors such as the increasing prevalence of Tourette syndrome and increasing research work related to the syndrome in this region. For instance, as per the report published by Tourette Canada in January 2022, Tourette syndrome affects approximately 1.0% of the population, although some recent studies suggest that the prevalence rate may be as high as 3.8%. Tics themselves are quite common in childhood, with studies showing that 24.0% of children may develop simple tics. Therefore, such instances indicate that the demand for Tourette syndrome treatment may increase, thereby propelling the market growth for treatments. 

Key product launches, high concentration of market players or manufacturer's presence, acquisitions and partnerships among major players, and public and private initiatives toward Tourette syndrome in the United States are some of the factors driving the growth of the Tourette syndrome treatment market in the country. For instance, the Tourette Association of America celebrates Tourette Syndrome Awareness Month from May 15 to June 15 every year to increase awareness about the syndrome among people. Thus, such instances are anticipated to drive the growth of the market in the country. 

Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated to grow in the North American region.


Competitive Landscape

The Tourette Syndrome Treatment market is consolidated and competitive, with most of the players competing to increase market share. Rising competition, rapid technological advancements, and a focus on research are key factors that have a strong impact on the market. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known, including AstraZeneca Plc, Boehringer Ingelheim International GmbH, Mylan NV, Otsuka Holdings Co. Ltd., Pfizer Inc., Reviva Pharmaceuticals Inc., and Auspex Pharmaceuticals, Inc., among others.

Recent Developments

  • In May 2022, Neurotherapeutics Ltd., a spin-out company from the University of Nottingham, developed a prototype device worn like a wristwatch that delivers electrical impulses to reduce the number and severity of tics experienced by individuals with Tourette Syndrome (TS). It is now being tested in a clinical trial across the United Kingdom.
  • In July 2021, a new study was done using a non-invasive technique to measure brain activity called high-density electroencephalography (hdEEG). The researchers at Yale School of Medicine assessed the impact of tic suppression on functional connectivity between brain regions.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Cases of Tourette Syndrome

      2. 4.2.2 Rising Focus on Tourette Syndrome Research

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness in Developing Region

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Product

      1. 5.1.1 Antipsychotics

      2. 5.1.2 Non Antipsychotics

    2. 5.2 Geography

      1. 5.2.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.2.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.2.3 Asia Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.2.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.2.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca Plc

      2. 6.1.2 Viatris Inc. (Mylan Inc.)

      3. 6.1.3 Otsuka Holdings Co. Ltd.

      4. 6.1.4 Reviva Pharmaceuticals Inc.

      5. 6.1.5 Teva Pharmaceutical Industries Ltd. (Auspex Pharmaceuticals, Inc.)

      6. 6.1.6 Catalyst Pharmaceutical

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Tourette Syndrome Treatment Market market is studied from 2019 - 2027.

The Global Tourette Syndrome Treatment Market is growing at a CAGR of 10.4% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

AstraZeneca Plc, Viatris Inc. (Mylan Inc.), Otsuka Pharmaceutical Co., Ltd., Reviva Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd. (Auspex Pharmaceuticals, Inc.) are the major companies operating in Global Tourette Syndrome Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!